Details for Patent: 11,896,597

Which drugs does patent 11,896,597 protect, and when does it expire?

Patent 11,896,597 protects ZEGFROVY and is included in one NDA.

This patent has thirty patent family members in sixteen countries.

Summary for Patent: 11,896,597

Title:	ErbB/BTK inhibitors
Abstract:	Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
Inventor(s):	Zhenfan YANG, Xiaolin Zhang
Assignee:	Dizal Jiangsu Pharmaceutical Co Ltd
Application Number:	US18/045,838
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 11,896,597

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No			Y	Y		TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-002	Jul 2, 2025		RX	Yes	Yes			Y	Y		TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY

International Family Members for US Patent 11,896,597

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	117390
Australia	2019215538
Australia	2023202151
Brazil	112020015726
Canada	3086616
China	111587244